en Radiation Biology Radiation Biology تحقيق بديع Original Research <div style="text-align: justify;"><span style="font-size:10pt"><span style="text-justify:newspaper"><span style="text-kashida-space:50%"><span style="line-height:119%"><span style="font-family:Calibri"><span style="color:black"><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-style:italic"><span style="font-weight:bold"><span style="language:en-US">Background:</span></span></span></span></span></span> <span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="language:en-US">This research was planned to disclose the clinical effect along with safety of programmed cell death protein 1/programmed death ligand-1 (PD-1/PD-L1) blockers in postoperative chemotherapy for advanced colorectal cancer. </span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-style:italic"><span style="font-weight:bold"><span style="language:en-US">Material and Methods: </span></span></span></span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="language:en-US">From June 2019 to June 2021, 23 advanced colorectal cancer patients received apatinib treatment and 28 advanced colorectal cancer patients received PD-1 inhibitors in our hospital were included. The safety and clinical efficacy of 2 therapeutic regimens were compared. </span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-style:italic"><span style="font-weight:bold"><span style="language:en-US">Results: </span></span></span></span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="language:en-US">Relative to apatinib group, the proportion of stable disease in patients accepting PD-1 blockers presented higher (P=0.010), the median progression-free survival (PFS) of patients accepting PD-1 blockers was longer (P=0.0209), the median PFS of patients with no liver metastasis who accepted PD-1 blockers presented longer (P<0.0001), the median PFS of Kirsten rat sarcoma viral oncogene homolog (KRAS) wild-type patients who received anti-PD-1 therapy presented longer (P=0.0288), and the median PFS of patients with left colon as primary site who received anti-PD-1 therapy presented longer (P=0.0105). Relative to the apatinib group, the incidence of adverse events in patients accepting PD-1 blockers was generally lower, but with no difference (P>0.05). </span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-style:italic"><span style="font-weight:bold"><span style="language:en-US">Conclusion: </span></span></span></span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="language:en-US">PD-1/PD-L1 blockers possess certain clinical efficacy and tolerability in treating advanced colorectal cancer.</span></span></span></span></span></span></span></span></span></div> Colorectal cancer, PD-1, PD-L1, apatinib, efficacy, safety. 31 36 http://ijrr.com/browse.php?a_code=A-10-1-1451&slc_lang=en&sid=1 G.L. Liu 7900319475328460032706 7900319475328460032706 No Department of Geriatrics and Respiratory Medicine, The Afffliated Tai'an City Central Hospital of Qingdao University, Tai'an 271000, Shandong, China W.R. Yang 7900319475328460032707 7900319475328460032707 No Department of Clinical Nutrition, The Afffliated Tai'an City Central Hospital of Qingdao University, Tai'an 271000, Shandong, China M. Cheng 7900319475328460032708 7900319475328460032708 No Department of Gastrointestinal Surgery, The Afffliated Tai'an City Central Hospital of Qingdao University, Tai'an 271000, Shandong, China C.L. Wang 7900319475328460032709 7900319475328460032709 No Department of Gastrointestinal Surgery, The Afffliated Tai'an City Central Hospital of Qingdao University, Tai'an 271000, Shandong, China M. Liu 7900319475328460032710 7900319475328460032710 No Department of Gastrointestinal Surgery, The Afffliated Tai'an City Central Hospital of Qingdao University, Tai'an 271000, Shandong, China X. Zheng zhengxiao@qdu.edu.cn 7900319475328460032711 7900319475328460032711 Yes Department of Gastrointestinal Surgery, The Afffliated Tai'an City Central Hospital of Qingdao University, Tai'an 271000, Shandong, China